Delta Air Lines has shed nearly 9% over the past week to close at $76.38, pulling further below the levels where insiders sold in August and dragging the stock to its weakest point in months — yet the data underneath tells a less bearish story than the price action implies.
The selloff is sector-wide, not Delta-specific. UAL fell more than 10% on the week, ALGT dropped 12%, and JBLU lost 12% as well. AAL and LUV declined 7% and 8% respectively. Delta's roughly 9% drop is in the middle of that pack — not a name-specific event, but a broad repricing of the sector. The prior note flagged insider selling near $92 and cautious options positioning; the stock has now fallen more than 17% from those August highs.
The lending market sends no alarm signal. Short interest has actually fallen 11.5% over the week, pulling the SI % of free float down to 3.5%. That decline follows a sharper unwind from around 25.5 million shares shorted in mid-August to roughly 22.5 million now — a meaningful reduction in short positioning even as the stock slides. Cost to borrow remains negligible at 0.44%, barely changed on the week. Borrow availability is extremely loose at 1,191% — more than eleven shares available for every one already borrowed — giving any prospective short seller ample room to press. That combination of falling short interest and loose availability suggests short sellers are not driving this week's weakness; they appear to be covering into the decline rather than building new positions.
Options positioning has actually eased from the defensive extremes flagged last week. The put/call ratio closed at 1.04, now slightly below its 20-day mean of 1.10, with a z-score of -1.0. That's a notable shift from the prior note's reading of 1.21, which was close to two standard deviations above the mean. Hedging demand has moderated. The borrow and options picture together paint a positioning setup that looks cautious rather than crowded — the people most bearish on this stock appear to be stepping back even as prices fall.
The Street remains firmly bullish, though price targets have moved lower. Raymond James maintained its Outperform on August 24, trimming its target from $104 to $98. TD Cowen held its Buy the same day, cutting from $112 to $105. Both firms acted after a period of upward revisions in mid-July, when Morgan Stanley raised to $125, JPMorgan to $114, and UBS to $112 following Q2 earnings. The mean analyst target now sits at $105, implying roughly 38% upside to the current price. Valuation remains modest — the trailing P/E is running near 10x, EV/EBITDA around 6.6x, and the price-to-book at 1.9x. On earnings quality, Delta ranks in the 88th percentile on EPS surprise and the 85th percentile on 90-day EPS momentum — the fundamental backdrop has not deteriorated to match the share price move.
Berkshire Hathaway remains the standout name on the institutional register, having raised its stake to 8.7% of the class in the most recent 13G/A amendment filed August 14, up from 6.1% previously. That's a material addition at a time when the stock was trading in the $80s. FMR filed a fresh 13G showing a 5.1% stake as recently as August 6. These are passive disclosures rather than activist filings — no 13D is on record — but Buffett building into a position at prices well above where the stock trades today is a data point the market is currently looking past. The insider data from January remains the most recent available and is too stale to carry weight in this note.
The next earnings print is October 9. That release will be the first since the stock retraced the entire post-Q2 earnings rally and then some. Whether the Street's bullish consensus on full-year earnings holds — factor scores show 73rd percentile on forward EPS growth and 88th on surprise — will be the central question heading into that date.
See the live data behind this article on ORTEX.
Open DAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
